For this reason, patients with advanced CRC should undergo genetic tumor analysis to detect KRAS/NRAS and BRAF mutations, HER2 amplifications, and microsatellite instability (MSI)/mismatch repair (MMR) status, among other biomarkers [4]. Here, KRAS is linked to colorectal carcinoma.